STOCK TITAN
  1. Home
  2. News
  3. TCRX

TScan Therapeutics, Inc. - TCRX STOCK NEWS

Welcome to our dedicated page for TScan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on TScan Therapeutics stock.

TScan Therapeutics, Inc. (NASDAQ: TCRX) is a pioneering biopharmaceutical company focused on developing advanced T-cell receptor (TCR) engineered T cell therapies (TCR-T) aimed at treating cancer. Specializing in harnessing novel T cell systems, TScan is at the forefront of extending the promise of immunotherapy to patients with hematologic malignancies and solid tumors.

The company's leading therapies, TSC-100 and TSC-101, are designed to eliminate residual leukemia and prevent relapse in patients with blood cancers such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) undergoing hematopoietic stem cell transplantation. These liquid tumor TCR-T therapy candidates are currently in development, reflecting TScan's commitment to improving patient outcomes.

TScan is also developing multiplexed TCR-T therapy candidates for treating various solid tumors, showcasing the company's versatility and innovative approach in the immunotherapy landscape. Recent recognition includes the RMAT designation granted for both TSC-100 and TSC-101, highlighting their potential significance in cancer treatment.

In addition to its groundbreaking therapeutic developments, TScan Therapeutics maintains strong partnerships and a robust financial foundation. The company frequently updates its stakeholders through transparent communication and investor relations, ensuring that all relevant developments and milestones are promptly shared.

For the latest news and updates, you can contact Heather Savelle, VP of Investor Relations, at 857-399-9840 or via email at hsavelle@tscan.com. Further inquiries can also be directed to Joyce Allaire, Managing Director at LifeSci Advisors, LLC, at 617-435-6602 or jallaire@lifesciadvisors.com.

News

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) reported positive initial data from Phase 1 heme program at the 65th American Society of Hematology (ASH) Annual Meeting, cleared INDs for four TCR-Ts, entered a collaboration with Amgen, and closed an underwritten public offering with net proceeds of $140.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
none
-
News

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced promising initial data from a Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL). Six treatment-arm patients achieved complete donor chimerism and MRD negativity, indicating no relapses, while one of four control-arm patients relapsed at six months. The company also announced plans to host a virtual KOL event to discuss the data presented at the ASH Annual Meeting and Exposition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) appoints R. Keith Woods, a highly experienced leader in the biopharmaceutical sector, to its Board of Directors. With over 30 years of life science experience, Mr. Woods brings expertise in commercialization, sales, global operations, and business strategy. His appointment is expected to support the growth of TScan and advance its compelling pipeline of T cell receptor (TCR)-engineered T cell therapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
management
News

TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) will host a virtual KOL event to discuss highlights from its poster presentation at the 65th ASH Annual Meeting and Exposition. The event will focus on lead TCR-T cell therapy candidates, TSC-100 and TSC-101, designed to target HA-1 and HA-2, respectively, to treat residual disease and prevent relapse in patients with acute myeloid leukemia, acute lymphocytic leukemia, or myelodysplastic syndromes undergoing allogeneic haploidentical hematopoietic cell transplantation with reduced intensity conditioning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.46%
Tags
conferences clinical trial
-
News

TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) appoints Justin McCue, Ph.D., as its Chief Technology Officer, bringing over 20 years of experience in biologics and cell therapy manufacturing. Dr. McCue's expertise will support the advancement of TScan's heme program and the launch of its multi-TCR-T solid tumor program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
management
-
News

TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) has been named one of the Top Places to Work in Massachusetts in the 16th annual employee-based survey project from The Boston Globe. The company focuses on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for cancer treatment. The recognition highlights the company's positive work environment and employee satisfaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.98%
Tags
none
News

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) reported financial results and provided a corporate update for Q3 2023. The company will present initial data from a heme malignancies Phase 1 trial at the 65th ASH Annual Meeting. Recent FDA clearance of IND for TSC-203-A0201 targeting PRAME. Ended Q3 with $215.4 million in cash and marketable securities, funding operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
earnings
-
News

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

Rhea-AI Summary
TScan Therapeutics announces the presentation of six posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The company's solid tumor program aims to deliver multiplexed T cell receptor (TCR)-engineered T cell therapy for solid tumors. They have initiated a screening protocol to test for target expression and the presence of HLA genes in patients' tumors. TScan expects to enroll the first patient in their treatment protocol this year. They are also developing TCR-T cell therapies targeting novel melanoma-associated antigen C2 (MAGE-C2) and plan to file an IND for TSC-201-B0702 by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.03%
Tags
clinical trial
-
News

TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition

Rhea-AI Summary
TScan Therapeutics, Inc. announces the acceptance of an abstract for poster presentation at the ASH Annual Meeting. The company will host a virtual KOL event featuring Dr. Monzr M. Al Malki to discuss the data presented at ASH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.73%
Tags
conferences
News

TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting

Rhea-AI Summary
TScan Therapeutics accepted six abstracts at the SITC Annual Meeting, presenting TCR-T cell therapies for cancer treatment. The presentation materials will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
conferences

FAQ

What is the current stock price of TScan Therapeutics (TCRX)?

The current stock price of TScan Therapeutics (TCRX) is $2.91 as of December 24, 2024.

What is the market cap of TScan Therapeutics (TCRX)?

The market cap of TScan Therapeutics (TCRX) is approximately 155.3M.

What is TScan Therapeutics, Inc.?

TScan Therapeutics, Inc. is a biopharmaceutical company specializing in T-cell receptor (TCR) engineered T cell therapies (TCR-T) for cancer treatment.

What are TScan's leading therapy candidates?

TScan's leading therapy candidates are TSC-100 and TSC-101, aimed at treating blood cancers like AML and ALL.

What recent recognition has TScan's therapies received?

TSC-100 and TSC-101 have been granted RMAT designation for their potential in treating AML, ALL, and MDS.

What types of cancer does TScan focus on?

TScan focuses on hematologic malignancies and various solid tumors.

How does TScan aim to improve cancer treatment?

TScan aims to improve cancer treatment by developing TCR-T therapies that target and eliminate residual cancer cells, reducing the risk of relapse.

How can I contact TScan's Investor Relations?

You can contact Heather Savelle, VP of Investor Relations, at 857-399-9840 or via email at hsavelle@tscan.com.

Where can I get the latest updates about TScan?

Latest updates and news can be found by contacting TScan's Investor Relations or visiting their official website.

What is the stock symbol for TScan Therapeutics, Inc.?

TScan Therapeutics, Inc. trades on NASDAQ under the symbol TCRX.

Who are the key contacts for media inquiries at TScan?

For media inquiries, you can contact Heather Savelle at TScan Therapeutics or Maghan Meyers at Argot Partners.

What are TScan's goals in immunotherapy?

TScan aims to extend the promise of immunotherapy through innovative TCR-T cell therapies that offer new hope to cancer patients.

Stock TCRX logo
TScan Therapeutics, Inc.

Nasdaq:TCRX

TCRX Rankings

#4090 Ranked by Market Cap
N/A Ranked by Dividends

TCRX Stock Data

155.31M
52.81M
0.82%
86%
4.3%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WALTHAM